These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32521566)

  • 1. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study.
    Touhouche AT; Cassagne M; Bérard E; Giordano-Labadie F; Didier A; Fournié P; Paul C; Tauber M
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):172-179. PubMed ID: 32521566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctivitis in dupilumab clinical trials.
    Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
    Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis.
    Maudinet A; Law-Koune S; Duretz C; Lasek A; Modiano P; Tran THC
    Ophthalmol Ther; 2019 Sep; 8(3):485-490. PubMed ID: 31230264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.
    Costedoat I; Wallaert M; Gaultier A; Vasseur R; Vanhaecke C; Viguier M; Cordelette C; Denoyer A; Ferrier le Bouëdec MC; Coutu A; Lamiaux M; Tran THC; Lacour JP; Elmaleh V; Tetart F; Gueudry J; Tauber M; Giordano-Labadie F; Cassagne M; Nosbaum A; Ouilhon C; Jachiet M; Tadayoni R; Dezoteux F; Staumont-Salle D; Bouleau J; Labalette P; Doan S; Soria A; Mortemousque B; Seneschal J; Barbarot S;
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1056-1063. PubMed ID: 36732052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis.
    Nettis E; Patella V; Lombardo C; Detoraki A; Macchia L; Di Leo E; Carbonara M; Canonica GW; Bonzano L
    Allergy; 2020 Oct; 75(10):2653-2661. PubMed ID: 32424957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.
    de Wijs LEM; Bosma AL; Erler NS; Hollestein LM; Gerbens LAA; Middelkamp-Hup MA; Kunkeler ACM; Nijsten TEC; Spuls PI; Hijnen DJ
    Br J Dermatol; 2020 Feb; 182(2):418-426. PubMed ID: 31145810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjunctivitis in patients with atopic dermatitis treated with dupilumab.
    Ferreira S; Torres T
    Drugs Context; 2020; 9():. PubMed ID: 32426016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.
    Thyssen JP; de Bruin-Weller MS; Paller AS; Leshem YA; Vestergaard C; Deleuran M; Drucker AM; Foelster-Holst R; Traidl-Hoffmann C; Eyerich K; Taieb A; Su JC; Bieber T; Cork MJ; Eichenfield LF; Guttman-Yassky E; Wollenberg A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1224-1231. PubMed ID: 31056788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study.
    Barbé J; Poreaux C; Remen T; Schoeffler A; Cloché V; Schmutz JL; Escobar G; Busztejn AC
    Int J Dermatol; 2021 Dec; 60(12):1520-1528. PubMed ID: 34037253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
    Achten RE; Van Luijk C; Van der Rijst L; Bakker D; Spekhorst L; Zuithoff N; Schuttelaar M; Romeijn G; Voorberg A; Kamsteeg M; Haeck I; De Graaf M; Thijs J; De Boer J; De Bruin-Weller M
    Acta Derm Venereol; 2022 Mar; 102():adv00666. PubMed ID: 35098318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment.
    Nahum Y; Mimouni M; Livny E; Bahar I; Hodak E; Leshem YA
    Br J Ophthalmol; 2020 Jun; 104(6):776-779. PubMed ID: 31554632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
    Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.
    Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M
    Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.
    Ou Z; Chen C; Chen A; Yang Y; Zhou W
    Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.